Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 18/20 | 0.57 |
| ▸ | HTR1B | P28222 | 15/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | CCR2 | P41597 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7489512 | 1.00 | HTR1D (0.57) | HTR1DHTR1BCHRM2DRD2CCR2 | |
| SCHEMBL7481584 | 0.86 | HTR1D (0.57) | HTR1DHTR1BCHRM2DRD2 | |
| SCHEMBL7486830 | 0.86 | HTR1D (0.69) | HTR1DHTR1BCHRM2DRD2 | |
| SCHEMBL7012805 | 0.85 | HTR1F (0.59) | HTR1DHTR1B | |
| SCHEMBL7480955 | 0.85 | HTR1D (0.54) | HTR1DHTR1BCHRM2DRD2 | |
| SCHEMBL30909111 | 0.85 | HTR1D (0.54) | HTR1DHTR1BCHRM2DRD2 | |
| SCHEMBL8548974 | 0.84 | DRD2 (0.45) | DRD2CCR2 | |
| SCHEMBL8552288 | 0.84 | DRD2 (0.43) | DRD2CCR2 | |
| SCHEMBL7484174 | 0.83 | HTR1D (0.57) | HTR1DHTR1BCHRM2DRD2 | |
| SCHEMBL27560329 | 0.82 | HTR1D (0.67) | HTR1DHTR1BCHRM2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1D 3/4885HTR1B 4/4885CHRM2 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.